Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.


Related Content

New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message
Large Simple Trials Need FDA Boost, IoM Report Says
FDA To Be More Vigilant About Proposed Clinical Trial Exclusions
Patient Exclusion Analysis Coming From FDA; Changes In Trial Recruitment Could Follow





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts